


Claims

1.



in which

$R^1$  means a monocyclic or bicyclic  $C_{6-12}$  aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I,

$C(NH)NH_2$ ,  $C(NH)NHR^4$ ,  $C(NH)NR^4R^{4'}$ ,  $C(NR^4)NH_2$ ,  $C(NR^4)NHR^{4'}$ ,

$C(NR^4)NR^4R^{4'}$ ,

$XOH$ ,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,

$XC(NOH)R^4$ ,  $XC(NOR^4)R^{4'}$ ,  $XC(NO(COR^4))R^{4'}$

$XCN$ ,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^{4'}$ ,  $XCONHR^4$ ,  $XCONHOH$ ,

$XCONHOR^4$ ,  $XCOSR^4$

$XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,

$SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^{4'}$ ,

0000000000-00000000

*Mark B  
cont*

$\text{NO}_2$ ,  $\text{XNH}_2$ ,  $\text{XNHR}^4$ ,  $\text{XNR}^4\text{R}^4'$ ,  $\text{XNHSO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)\text{SO}_2\text{R}^4'$ ,  
 $\text{XNR}^4\text{SO}_2\text{R}^4'$ ,  
 $\text{XNCOR}^4$ ,  $\text{XNHCOOR}^4$ ,  $\text{XNHCONHR}^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl,  $\text{R}^4$ , whereby two substituents at  $\text{R}^1$ , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxyl, ethane-1,2-diylbisoxyl, propane-1,3-diyl, butane-1,4-diyl,

$\text{R}^2$  means a monocyclic or bicyclic  $\text{C}_{6-10}$  aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I,

$\text{XOH}$ ,  $\text{XOR}^4$ ,  $\text{XOCOR}^4$ ,  $\text{XOCONHR}^4$ ,  $\text{XOCOOR}^4$ ,  $\text{XCOR}^4$ ,  $\text{XC}(\text{NOH})\text{R}^4$ ,  $\text{XC}(\text{NOR}^4)\text{R}^4'$ ,  $\text{XC}(\text{NO}(\text{COR}^4))\text{R}^4'$ ,  $\text{XCOOH}$ ,  $\text{XCOOR}^4$ ,  $\text{XCONH}_2$ ,  $\text{XCONHR}^4$ ,  $\text{XCONR}^4\text{R}^4'$ ,  $\text{XCONHOH}$ ,  $\text{XCONHOR}^4$ ,  $\text{XCOSR}^4$ ,  $\text{XSR}^4$ ,  $\text{XSOR}^4$ ,  $\text{XSO}_2\text{R}^4$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NHR}^4$ ,  $\text{SO}_2\text{NR}^4\text{R}^4'$ ,  $\text{NO}_2$ ,  $\text{XNHR}^4$ ,  $\text{XNR}^4\text{R}^4'$ ,  $\text{XNHSO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)\text{SO}_2\text{R}^4'$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4'$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl,  $\text{R}^4$ ,

TOKYO 232-0026

*John B. Smith cont.*

whereby two substituents at R<sup>2</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl,

R<sup>3</sup> means one or two substituents, which form, independently of one another:

hydrogen,

F, Cl, Br, I,

XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,

XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4</sup>, XC(NO(COR<sup>4</sup>))R<sup>4</sup>,

XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONHR<sup>4</sup>, XCONR<sup>4</sup>R<sup>4</sup>', XCONHOH,

XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>,

SO<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>',

NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4</sup>',

XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4</sup>', XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4</sup>'),

XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, tetrahydro-2,5-

dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl,

2,7-dihydro-2,7-dioxoisoindol-1-yl, or R<sup>3</sup> can be R<sup>4</sup>,

whereby two substituents at R<sup>3</sup>, if they are in ortho-position to one another, can be linked to one another

in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl,

R<sup>4</sup> and R<sup>4</sup>', independently of one another, mean C<sub>1-4</sub>

perfluoroalkyl, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkinyl, C<sub>3</sub>-

<sub>7</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-7</sub> cycloalkyl), C<sub>1-3</sub> alkyl-C<sub>6-10</sub>

1  
2  
cont

aryl,  $C_{1-3}$  alkyl-5 to 10-membered heteroaryl, with 1-4 N, S or O atoms,  $C_{6-10}$  aryl or 5- to 10-membered heteroaryl with 1-4 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ ,  $C_2F_5$  or else can carry an annelated methanediylbisoxo group or ethane-1,2-diylbisoxo group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl,

$R^5$  and  $R^{5'}$ , independently of one another, mean  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkinyl, whereby a carbon atom can be exchanged for O, S, SO,  $SO_2$ , NH, N  $C_{1-3}$  alkyl or N  $C_{1-3}$  alkanoyl,

$C_{3-7}$  cycloalkyl- $C_{0-3}$  alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl,

$C_{6-10}$  aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms from N, S, and O, whereby the mentioned alkyl, alkenyl and alkinyl chains can be substituted

SEARCHED  
SERIALIZED  
INDEXED  
FILED

(1)  
(2)  
(3)

with one of the previously mentioned cycloalkyls, aryls or heteroaryls,

whereby all previously mentioned alkyl and cycloalkyl radicals with up to two substituents consisting of  $\text{CF}_3$ ,  $\text{C}_2\text{F}_5$ ,  $\text{OH}$ ,  $\text{O C}_{1-3}$  alkyl,  $\text{NH}_2$ ,  $\text{NH C}_{1-3}$  alkyl,  $\text{NH C}_{1-3}$  alkanoyl,  $\text{N}(\text{C}_{1-3}\text{ alkyl})_2$ ,  $\text{N}(\text{C}_{1-3}\text{ alkyl})(\text{C}_{1-3}\text{ alkanoyl})$ ,  $\text{COOH}$ ,  $\text{CONH}_2$ ,  $\text{COO C}_{1-3}$  alkyl and all previously mentioned aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{CH}_3$ ,  $\text{C}_2\text{H}_5$ ,  $\text{NO}_2$ ,  $\text{OCH}_3$ ,  $\text{OC}_2\text{H}_5$ ,  $\text{CF}_3$ ,  $\text{C}_2\text{F}_5$  or else can carry an annelated methanediylbisoxo, ethane-1,2-diylbisoxo group,

or  $\text{R}^5$  and  $\text{R}^{5'}$  together with the nitrogen atom form a 5-to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  alkoxy- $\text{C}_{0-2}$  alkyl,  $\text{C}_{1-4}$  alkoxy-carbonyl, aminocarbonyl or phenyl,

**A** means  $\text{C}_{1-10}$  alkanediyl,  $\text{C}_{2-10}$  alkenediyl,  $\text{C}_{2-10}$  alkinediyl, ( $\text{C}_{0-5}$  alkanediyl- $\text{C}_{3-7}$  cycloalkanediyl- $\text{C}_{0-5}$  alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $\text{C}_{1-3}$  alkyl or  $\text{C}_{1-3}$  alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH,  $\text{N C}_{1-3}$  alkyl,  $\text{N C}_{1-3}$  alkanoyl, and whereby alkyl or

*for  
B1  
cont*

cycloalkyl groups can be substituted with up to two substituents consisting of =O, OH, O C<sub>1-3</sub> alkyl, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, N(C<sub>1-3</sub> alkyl) (C<sub>1-3</sub> alkanoyl),

B means COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHNH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>5</sup>, SO<sub>2</sub>NR<sup>5</sup>R<sup>5'</sup>, PO<sub>3</sub>H, PO(OH)(OR<sup>5</sup>), PO(OR<sup>5</sup>)(OR<sup>5'</sup>), PO(OH)(NHR<sup>5</sup>), PO(NHR<sup>5</sup>)(NHR<sup>5'</sup>), tetrazolyl,

in each case bonded to a carbon atom of group A, or the entire group Y-A-B N(SO<sub>2</sub>R<sup>4</sup>) (SO<sub>2</sub>R<sup>4'</sup>) or NSO<sub>2</sub>R<sup>4</sup>,

X means a bond, CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>, CH(CH<sub>3</sub>), (CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>2</sub>CH<sub>3</sub>), CH(CH<sub>3</sub>)CH<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>),

Y means O, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, NSO<sub>2</sub>R<sup>4</sup>,

provided that if Y means NH, NR<sup>4</sup>, NCOR<sup>4</sup> or NSO<sub>2</sub>R<sup>4</sup>, and

a) substituent R<sup>2</sup> contains a nitrogen-containing, saturated heterocyclic compound, this heterocyclic compound is not substituted in the imine nitrogen with H, methyl, ethyl, propyl or isopropyl,  
or

b) in optionally present groups XNHR<sup>4</sup> or XNR<sup>4</sup>R<sup>4'</sup> of substituent R<sup>2</sup>, R<sup>4</sup> and/or R<sup>4'</sup> does not mean C<sub>1-4</sub> alkyl, that B does not mean COOH, SO<sub>3</sub>H, PO<sub>3</sub>H<sub>2</sub> or tetrazolyl at the same time, and R<sup>1</sup> and R<sup>2</sup>, independently of one another, mean C<sub>5-6</sub> heteroaryl or phenyl, if the latter, independently of one another, are unsubstituted, or are substituted simply with C<sub>1-6</sub>

alkyl, C<sub>1-4</sub> perfluoroalkyl, O C<sub>1-6</sub> alkyl, O C<sub>1-4</sub> perfluoroalkyl, COOH, COO C<sub>1-6</sub> alkyl, CO C<sub>1-6</sub> alkyl, CONH<sub>2</sub>, CONHR<sup>4</sup>, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>4</sup>, NHSO<sub>2</sub>R<sup>4</sup>, or with 1 or 2 halogen atoms from the group that consists of F, Cl, Br, and I, and whereby the following compounds are excluded:

[ (1,2-Diphenyl-1H-benzimidazol-6-yl)oxy]acetic acid methyl ester,

5- [ (1,2-diphenyl-1H-benzimidazol-6-yl)oxy]pentanoic acid methyl ester,

4- [ (1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid ethyl ester,

5- [ [1- (4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy] - pentanoic acid methyl ester,

6- [ [1- (4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester,

5- [ [1- (4-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

5- [ [1- [4- [(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

5- [ [1- [4- [(acetyl)amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5- [ [1- (3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

6- [ [1- (3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester,

5- [ [1- (3-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

*M*  
*B*  
*W*

5-[[1-[3-[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

5-[[1-[3-[(acetyl)amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester.

2. Benzimidazoles according to claim 1, characterized in  
that

*S*  
*C*

$R^1$  means a monocyclic or bicyclic  $C_{6-12}$  aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br,

XOH,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,

$XCOR^4$ , XCN,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^4'$ ,  $XCONHR^4$ ,

$XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $NO_2$ ,  $XNHR^4$ ,  $XNR^4R^4'$ ,  $R^4$ ,

whereby two substituents at  $R^1$ , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.

3. Benzimidazoles according to claim 1 or 2, wherein

$R^2$  means a monocyclic or bicyclic  $C_{6-10}$  aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or

heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br,

XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCOHR<sup>4</sup>, XOCOOR<sup>4</sup>,  
 XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>,  
 XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONHR<sup>4</sup>, XCONR<sup>4'R<sup>4'</sup>, XCONHOH,  
 XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>,  
 XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4'R<sup>4'</sup>,  
 NO<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4'R<sup>4'</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)SO<sub>2</sub>R<sup>4'</sup>, XNR<sup>4'SO<sub>2</sub>R<sup>4'</sup>,  
 R<sup>4</sup>,</sup></sup></sup></sup>

whereby two substituents at R<sup>2</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

4. Benzimidazoles according to one of claims 1-3, wherein R<sup>3</sup> means one or two substituents, which, independently of one another, can be:

hydrogen, F, Cl, Br,

XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCOHR<sup>4</sup>, XOCOOR<sup>4</sup>,  
 XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>,  
 XCN, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4'R<sup>4'</sup>,  
 NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4'N<sup>4'</sup>,  
 XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4'SO<sub>2</sub>R<sup>4'</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)SO<sub>2</sub>R<sup>4'</sup>,  
 XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, or R<sup>4</sup>, whereby two substituents R<sup>3</sup>, if they are in ortho-position to one</sup></sup></sup>

another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, or butane-1,4-diyl.

5. Benzimidazoles according to one of claims 1-4, wherein R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkinyl, C<sub>3-6</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-6</sub> cycloalkyl), phenyl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the phenyl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl.

6. Benzimidazoles according to one of claims 1-5, wherein R<sup>5</sup> and R<sup>5'</sup>, independently of one another, can be C<sub>1-6</sub> alkyl, whereby a carbon atom can be exchanged for O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl, C<sub>3-7</sub> cycloalkyl-C<sub>0-3</sub> alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, whereby the mentioned C<sub>1-6</sub> alkyl part can be substituted with one of the previously mentioned

SEARCHED  
SERIALIZED  
INDEXED  
FILED  
JULY 26 1968

cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from N, S or O, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of  $\text{CF}_3$ , OH,  $\text{O C}_{1-3}$  alkyl, and the previously mentioned heteroaryl groups with one or two substituents that consist of F, Cl,  $\text{CF}_3$ ,  $\text{CH}_3$ ,  $\text{C}_2\text{H}_5$ ,  $\text{OCH}_3$ ,  $\text{OC}_2\text{H}_5$ , or  $\text{R}^5$  and  $\text{R}^5'$  together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  alkoxy- $\text{C}_{0-2}$  alkyl,  $\text{C}_{1-4}$  alkoxy-carbonyl, aminocarbonyl or phenyl.

7. Benzimidazoles according to one of claims 1-6, wherein
- A** means  $\text{C}_{1-10}$  alkanediyl,  $\text{C}_{2-10}$  alkenediyl,  $\text{C}_{2-10}$  alkinediyl, ( $\text{C}_{0-5}$  alkanediyl- $\text{C}_{3-7}$  cycloalkanediyl- $\text{C}_{0-5}$  alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, or in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $\text{C}_{1-3}$  alkyl or  $\text{C}_{1-3}$  alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH,  $\text{N C}_{1-3}$  alkyl, or  $\text{N C}_{1-3}$  alkanoyl.
8. Benzimidazoles according to one of claims 1-7, wherein
- B** means COOH,  $\text{COOR}^5$ ,  $\text{CONH}_2$ ,  $\text{CONHR}^5$ ,  $\text{CONR}^5\text{R}^5'$ , CONHOH,  $\text{CONHOR}^5$  or tetrazolyl,  
in each case bonded to a carbon atom of group **A**.

SEARCHED - INDEXED - COPIED - FILED

9. Benzimidazoles according to one of claims 1-8, wherein

X means a bond or methylene.

10. Benzimidazoles according to one of claims 1-9, wherein

Y means O.

11. [(1,2-Diphenyl-1H-benzimidazol-6-yl)oxy]acetic acid

isopropyl ester

3-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]propanoic acid

methyl ester

2-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]propanoic acid

methyl ester

4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid

isopropyl ester

5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]pentanoic acid

isopropyl ester

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid

methyl ester

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid

isopropyl ester

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-methoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-  
y1)oxy]hexanamide

N-(phenylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-  
y1)oxy]hexanamide

N-hydroxy-6-[(1,2-diphenyl-1H-benzimidazol-6-  
y1)oxy]hexanamide

7-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]heptanoic acid  
methyl ester

*Sus C4*  
Cont.

~~6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid isopropyl ester~~

~~6-[[2-phenyl-1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester~~

~~6-[[2-phenyl-1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-6-yloxy]hexanoic acid isopropyl ester~~

~~6-[[1-(3-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester~~

~~6-[[1-(3-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid isopropyl ester~~

~~6-[[1-(3-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid~~

~~6-[[1-(4-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester~~

~~6-[[1-(4-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid isopropyl ester~~

~~6-[[1-(3-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester~~

~~6-[[1-(3-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid isopropyl ester~~

~~6-[[1-(4-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester~~

~~6-[[1-(4-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid isopropyl ester~~

~~6-[[1-(3-methylphenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester~~

*Sub  
C4  
cont.*

6-[[1-(3-methylphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid isopropyl ester

6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid isopropyl ester

6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[1-(3,5-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[1-(3,5-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid isopropyl ester

6-[[1-(3-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[1-(3,4-dimethoxyphenyl)-2-phenyl-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[1-[3,4-(methylenedioxy)phenyl]-2-phenyl-1H-benzimidazol-  
6-yl]oxy]hexanoic acid methyl ester

6-[[1-[3,4-(methylenedioxy)phenyl]-2-phenyl-1H-benzimidazol-  
6-yl]oxy]hexanoic acid

6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-  
yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-  
yl]oxy]hexanoic acid

6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1-[4-(N,N-dimethylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-[4-(N,N-dimethylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[1-phenyl-2-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[2-(3-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(3-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[2-(4-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[2-(4-methylphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-methylphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1-phenyl-2-(4-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[(1,2-diphenyl-5-nitro-1H-benzimidazol-6-yl)oxy]hexanoic acid methyl ester

6-[(1,2-diphenyl-5-nitro-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester

*Sub C4 cont.*

6-[[5-[(4-bromophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1,2-diphenyl-5-[(3-methylphenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1,2-diphenyl-5-[(4-methylphenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1,2-diphenyl-5-[(4-methoxyphenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1,2-diphenyl-5-[[[(4-trifluoromethyl)phenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-[[[4-(acetylamino)phenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-[[bis(3-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[1,2-diphenyl-5-[(propylsulfonyl)amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-[(benzylsulfonyl)amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

2-[2-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]ethoxy]acetic acid methyl ester

3-[2-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]ethoxy]propanoic acid methyl ester

Sub C4  
cont.

6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid ethyl ester

6-[[4-acetyl-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-[4-(thiomethyl)phenyl]-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-[(4-(thiomethyl)phenyl]-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid methyl ester

N-(phenylmethoxy)-6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]-hexanamide

N,N-dimethyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopropyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-pyrrolidin-1-ylhexan-1-one

5-[[5-[[4-chlorophenyl]sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

- Sub  
C4  
cont.
- 6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[4-(acetyloxy)-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[4-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[4-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid
- 6-[[7-methyl-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
12. 6-[[2-Phenyl-1-(3-pyridyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester
- 6-[[2-phenyl-1-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[2-phenyl-1-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[2-(4-fluoro-phenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[2-(4-methoxyphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[2-(4-bromophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
- 6-[[2-[4-(trifluoromethyl)phenyl]-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-2-(4-fluorophenyl)-1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

4-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]butanoic acid methyl ester

5-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5-[[5-[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

6-[[5-[(4-(trifluoromethyl)phenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonylmethylamino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[1-(3-fluorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-nitrophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

N-(cyclopropylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(cyclopropylmethoxy)-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanamide

N-isobutoxy-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(3-methoxypropyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-morpholin-1-ylhexan-1-one

N,N-di(-2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopentyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-2-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-3-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopropyl-6-[(1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N,N-dimethyl-6-[(1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N,N-diethyl-6-[(1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutyl-6-[(1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-cyclopropyl-6-[(1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-cyclobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-*tert*-butyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

(R)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]1-(2-methoxymethyl)-pyrrolidin-1-ylhexan-1-one

N-(3-imidazol-1-yl-propyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-pyridin-2-ylethyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(3-methoxypropyl)-6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]heptanamide

6-[[1-(4-methylphenyl)-2-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(3-indolyl)-1-(4-methylphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester


6-[[1-(4-methylphenyl)-2-(5-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester.

*M* 13. Use of a compound according to one of claims 1-12 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

14. Pharmaceutical agent, wherein it contains one or more compounds according to one of claims 1-12 and one or more vehicles.

15. Use of a benzimidazole of general formula II



in which

$R^1$  means a monocyclic or bicyclic  $C_{6-12}$  aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

JAN  
B2  
CML

F, Cl, Br, I, C(NH)NH<sub>2</sub>, } C(NH)NHR<sup>4</sup>, C(NH)NR<sup>4</sup>R<sup>4'</sup>,  
 C(NR<sup>4</sup>)NH<sub>2</sub>, C(NR<sup>4</sup>)NHR<sup>4'</sup>, C(NR<sup>4</sup>)NR<sup>4</sup>R<sup>4'</sup>, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>,  
 XOCOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>,  
 XC(NO(COR<sup>4</sup>))R<sup>4'</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONR<sup>4</sup>R<sup>4'</sup>,  
 XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>,  
 SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>,  
 XNHSO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>), XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>,  
 XNHCONHR<sup>4</sup>, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxoisoindol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R<sup>4</sup>, whereby two substituents at R<sup>1</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl,

**R<sup>2</sup>** means a monocyclic or bicyclic C<sub>6-10</sub> aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I, C(NH)NH<sub>2</sub>, C(NH)NHR<sup>4</sup>, C(NH)NR<sup>4</sup>R<sup>4'</sup>, C(NR<sup>4</sup>)NH<sub>2</sub>, C(NR<sup>4</sup>)NHR<sup>4'</sup>, C(NR<sup>4</sup>)NR<sup>4</sup>R<sup>4'</sup>, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONR<sup>4</sup>R<sup>4'</sup>, XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>,

J  
P  
C

XNHSO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>), XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R<sup>4</sup>, whereby two substituents at R<sup>2</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediyl-bisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl,

R<sup>3</sup> stands for one or two substituents, which form, independently of one another:

hydrogen, F, Cl, Br, I, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONHR<sup>4</sup>, XCONR<sup>4</sup>R<sup>4'</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>), XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R<sup>4</sup>, whereby two substituents at R<sup>3</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl,

R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean C<sub>1-4</sub> perfluoroalkyl, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-7</sub> cycloalkyl), C<sub>1-3</sub> alkyl-C<sub>6-10</sub> aryl, C<sub>1-3</sub> alkyl 5 to 10-membered heteroaryl, with 1-4

*John B. Zorn*

N, S or O atoms,  $C_{6-10}$  aryl or 5- to 10-membered heteroaryl with 1-4 N, S or O atoms, whereby the  $C_{6-10}$  aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ ,  $C_2F_5$  or else can carry an annelated methanediylbisoxy group or ethane-1,2-diylbisoxy group, and in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl,

$R^5$  and  $R^{5'}$ , independently of one another, mean hydrogen,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkinyl, whereby a carbon atom can be exchanged for O, S, SO,  $SO_2$ , NH, N  $C_{1-3}$  alkyl or N  $C_{1-3}$  alkanoyl,

$C_{3-7}$  cycloalkyl- $C_{0-3}$  alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl,

$C_{6-10}$  aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms from N, S, and O, whereby the mentioned alkyl, alkenyl and alkinyl chains can be substituted with one of the previously mentioned cycloalkyls, aryls or heteroaryls,

*Part B 2 cont*

whereby all previously mentioned alkyl and cycloalkyl radicals with up to two substituents consisting of  $\text{CF}_3$ ,  $\text{C}_2\text{F}_5$ , OH, O  $\text{C}_{1-3}$  alkyl, NH<sub>2</sub>, NH  $\text{C}_{1-3}$  alkyl, NH  $\text{C}_{1-3}$  alkanoyl, N ( $\text{C}_{1-3}$  alkyl)<sub>2</sub>, N( $\text{C}_{1-3}$  alkyl) ( $\text{C}_{1-3}$  alkanoyl), COOH, CONH<sub>2</sub>, COO  $\text{C}_{1-3}$  alkyl and all previously mentioned aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub> or else can carry an annelated methanediylbisoxo, ethane-1,2-diylbisoxo group, or R<sup>5</sup> and R<sup>5'</sup> together with the nitrogen atom form a 5-to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>0-2</sub> alkyl, C<sub>1-4</sub> alkoxy-carbonyl, aminocarbonyl or phenyl,

**A** means  $C_{1-10}$  alkanediyl,  $C_{2-10}$  alkenediyl,  $C_{2-10}$  alkinediyl, ( $C_{0-5}$  alkanediyl- $C_{3-7}$  cycloalkanediyl- $C_{0-5}$  alkanediyl), ( $C_{0-5}$  alkanediylarylene- $C_{0-5}$  alkanediyl), ( $C_{0-5}$  alkanediyl-heteroarylene- $C_{0-5}$  alkanediyl), whereby the aryl and heteroaryl groups can be substituted with one or two substituents that consist of F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ ,  $C_2F_5$ , whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl,

*John B. Z. Cmt*

whereby in the mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, NSO<sub>2</sub>R<sup>4</sup>,

and whereby alkyl or cycloalkyl groups can be substituted with up to two substituents consisting of F, OH, OR<sup>4</sup>, OCOR<sup>4</sup>, =O, NH<sub>2</sub>, NR<sup>4</sup>R<sup>4'</sup>, NHCOR<sup>4</sup>, NHCOOR<sup>4</sup>, NHCONHR<sup>4</sup>, NHSO<sub>2</sub>R<sup>4</sup>, SH, SR<sup>4</sup>,

B means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COR<sup>5</sup>, C(NOH)R<sup>5</sup>, C(NOR<sup>5</sup>)R<sup>5'</sup>,

C(NO(COR<sup>5</sup>))R<sup>5'</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHNH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>,

CONHOH, CONHOR<sup>5</sup>, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>5</sup>, SO<sub>2</sub>NR<sup>5</sup>R<sup>5'</sup>,

PO<sub>3</sub>H, PO(OH)(OR<sup>5</sup>), PO(OR<sup>5</sup>)(OR<sup>5'</sup>), PO(OH)(NHR<sup>5</sup>),

PO(NHR<sup>5</sup>)(NHR<sup>5'</sup>),

tetrazolyl, respectively bonded to a carbon atom of group A,

or the entire group Y-A-B N(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>) or NHSO<sub>2</sub>R<sup>4</sup>,

X means a bond, CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>, CH(CH<sub>3</sub>), (CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>2</sub>CH<sub>3</sub>), CH(CH<sub>3</sub>)CH<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>),

Y means a bond, O, S, SO, SO<sub>2</sub>, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, NSO<sub>2</sub>R<sup>4</sup>,

for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

16. Use according to claim 15, whereby in general formula II,

R<sup>1</sup> means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl

*Sub B2 cont*

group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br,

XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,

XCOR<sup>4</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONR<sup>4</sup>R<sup>4'</sup>, XCONHR<sup>4</sup>,

XCONHOH,

XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, NO<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>,

R<sup>4</sup>,

whereby two substituents at R<sup>1</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.

17. Use according to claim 15 or 16, whereby in general

*Sub A3*

formula II,

R<sup>2</sup> means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl group or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,

XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>,

$\text{XC}(\text{NOR}^4)\text{R}^4'$ ,  $\text{XC}(\text{NO}(\text{COR}^4))\text{R}^4'$ ,  $\text{XCN}$ ,  $\text{XCOOH}$ ,  $\text{XCOOR}^4$ ,  $\text{XCONH}_2$ ,  $\text{XCONR}^4\text{R}^4'$ ,

$\text{XCONHR}^4$ ,  $\text{XCONHOH}$ ,  $\text{XCONHOR}^4$ ,  $\text{XCOSR}^4$ ,  $\text{XSR}^4$ ,  $\text{XSOR}^4$ ,  $\text{XSO}_2\text{R}^4$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NHR}^4$ ,  $\text{SO}_2\text{NR}^4\text{R}^4'$ ,  $\text{NO}_2$ ,  $\text{XNH}_2$ ,  $\text{XNHR}^4$ ,  $\text{XNR}^4\text{R}^4'$ ,  $\text{XNHSO}_2\text{R}^4$ ,

$\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4')$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4'$ ,  $\text{XNCOR}^4$ ,  $\text{XNHCOR}^4$ ,  $\text{XNHCONHR}^4$ ,  $\text{R}^4$ ,

whereby two substituents at  $\text{R}^2$ , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxyl, ethane-1,2-diylbisoxyl, propane-1,3-diyl, butane-1,4-diyl.

18. Use according to claims 15-17, whereby in general formula II

$\text{R}^3$  stands for one or two substituents, which independently of one another, mean:

hydrogen, F, Cl, Br, XOH, XOR<sup>4</sup>, XCOR<sup>4</sup>, XCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4</sup>', XC(NO(COR<sup>4</sup>))R<sup>4</sup>', XCN, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>', NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4</sup>', XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4</sup>',

$\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4')$ , XNCOR<sup>4</sup>, XNHCOR<sup>4</sup>, XNHCONHR<sup>4</sup>, or R<sup>4</sup>, whereby two substituents R<sup>3</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxyl, ethane-1,2-diylbisoxyl, propane-1,3-diyl, butane-1,4-diyl.

09759260 - 242602

19. Use according to claims 15-18, whereby in general formula II

R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkinyl, C<sub>3-6</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-6</sub> cycloalkyl), C<sub>1-3</sub> alkylaryl, C<sub>1-3</sub> alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub> or else can carry an annelated methanediylbisoxo or ethane-1,2-diylbisoxo group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl.

20. Use according to claims 15-19, whereby in general formula II

R<sup>5</sup> and R<sup>5'</sup>, independently of one another, can be C<sub>1-6</sub> alkyl, whereby a carbon atom can be exchanged for O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl, C<sub>3-7</sub> cycloalkyl-C<sub>0-3</sub> alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, whereby the

00252600-04760A

mentioned C<sub>1-6</sub> alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from the group that consists of N, S or O, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF<sub>3</sub>, OH, O C<sub>1-3</sub> alkyl, and the previously mentioned heteroaryl groups can be substituted with one or two substituents that consist of F, Cl, CF<sub>3</sub>, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, or R<sup>5</sup> and R<sup>5'</sup> together with the nitrogen atom form a 5-to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>0-2</sub> alkyl, C<sub>1-4</sub> alkoxy-carbonyl, aminocarbonyl or phenyl.

21. Use according to claims 15-20, whereby in general formula II

A means C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), or (C<sub>0-5</sub> alkanediyl-heteroarylene-C<sub>0-5</sub> alkanediyl), whereby an optionally present heteroaryl group can be substituted with one or two substituents that consist of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N

and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, whereby in an aliphatic chain, a carbon atom or two carbon atoms can be exchanged for O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl, NSO<sub>2</sub> C<sub>1-3</sub> alkyl, and whereby alkyl or cycloalkyl parts can be substituted with up to two F atoms or one of the substituents that consists of OH, O C<sub>1-3</sub> alkyl, O C<sub>1-3</sub> alkanoyl, =O, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl) (C<sub>1-3</sub> alkanoyl), NHCOO C<sub>1-3</sub> alkyl, NHCONH C<sub>1-3</sub> alkyl, NHSO<sub>2</sub> C<sub>1-3</sub> alkyl, SH, S C<sub>1-3</sub> alkyl.

22. Use according to claims 15-21, whereby in general formula II

B means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, or tetrazolyl, in each case bonded to a carbon atom of group A.

23. Use according to claims 15-22, whereby in general formula II,

X means a bond or CH<sub>2</sub>.

24. Use according to claims 15-23, whereby in general formula II,

Y means a bond, O, S, NH, NR<sup>4</sup>, NCOR<sup>4</sup> or NSO<sub>2</sub>R<sup>4</sup>.

Add  
B<sup>3</sup>

Add  
C<sup>8</sup>